Paramount Global Statistics
Total Valuation
iSpecimen has a market cap or net worth of $5.09 million. The enterprise value is $4.61 million.
Important Dates
The next estimated earnings date is Tuesday, August 19, 2025, before market open.
| Earnings Date | Aug 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
iSpecimen has 3.98 million shares outstanding. The number of shares has increased by 159.38% in one year.
| Current Share Class | 3.98M |
| Shares Outstanding | 3.98M |
| Shares Change (YoY) | +159.38% |
| Shares Change (QoQ) | +105.35% |
| Owned by Insiders (%) | 1.00% |
| Owned by Institutions (%) | 2.61% |
| Float | 3.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.19 |
| Forward PS | n/a |
| PB Ratio | 1.92 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.31, with a Debt / Equity ratio of 0.18.
| Current Ratio | 0.31 |
| Quick Ratio | 0.28 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -48.14 |
Financial Efficiency
Return on equity (ROE) is -265.37% and return on invested capital (ROIC) is -158.94%.
| Return on Equity (ROE) | -265.37% |
| Return on Assets (ROA) | -73.40% |
| Return on Invested Capital (ROIC) | -158.94% |
| Return on Capital Employed (ROCE) | -590.90% |
| Revenue Per Employee | $335,776 |
| Profits Per Employee | -$468,920 |
| Employee Count | 24 |
| Asset Turnover | 0.83 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.40% in the last 52 weeks. The beta is 1.65, so iSpecimen's price volatility has been higher than the market average.
| Beta (5Y) | 1.65 |
| 52-Week Price Change | -74.40% |
| 50-Day Moving Average | 1.14 |
| 200-Day Moving Average | 2.11 |
| Relative Strength Index (RSI) | 51.11 |
| Average Volume (20 Days) | 526,355 |
Short Selling Information
The latest short interest is 47,626, so 1.20% of the outstanding shares have been sold short.
| Short Interest | 47,626 |
| Short Previous Month | 44,278 |
| Short % of Shares Out | 1.20% |
| Short % of Float | 1.21% |
| Short Ratio (days to cover) | 0.62 |
Income Statement
In the last 12 months, iSpecimen had revenue of $8.06 million and -$11.25 million in losses. Loss per share was -$9.56.
| Revenue | 8.06M |
| Gross Profit | 3.10M |
| Operating Income | -11.37M |
| Pretax Income | -10.20M |
| Net Income | -11.25M |
| EBITDA | -11.11M |
| EBIT | -11.37M |
| Loss Per Share | -$9.56 |
Full Income StatementBalance Sheet
The company has $782,563 in cash and $300,147 in debt, giving a net cash position of $482,416 or $0.12 per share.
| Cash & Cash Equivalents | 782,563 |
| Total Debt | 300,147 |
| Net Cash | 482,416 |
| Net Cash Per Share | $0.12 |
| Equity (Book Value) | 1.67M |
| Book Value Per Share | 0.67 |
| Working Capital | -3.39M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.29 million and capital expenditures -$47,410, giving a free cash flow of -$7.33 million.
| Operating Cash Flow | -7.29M |
| Capital Expenditures | -47,410 |
| Free Cash Flow | -7.33M |
| FCF Per Share | -$1.84 |
Full Cash Flow StatementMargins
Gross margin is 38.45%, with operating and profit margins of -141.04% and -139.65%.
| Gross Margin | 38.45% |
| Operating Margin | -141.04% |
| Pretax Margin | -139.65% |
| Profit Margin | -139.65% |
| EBITDA Margin | -137.83% |
| EBIT Margin | -141.04% |
| FCF Margin | n/a |
Dividends & Yields
iSpecimen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -159.38% |
| Shareholder Yield | -159.38% |
| Earnings Yield | -220.94% |
| FCF Yield | -143.99% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 16, 2024. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 16, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
iSpecimen has an Altman Z-Score of -19.59 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -19.59 |
| Piotroski F-Score | 2 |
